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ABSTRACT:   
                                 A new series of non peptide angiotensin(A-II) receptor 
antagonist has been prepared.  This N-(biphenyl methyl) 
imidazoles e.g. 5-substituted (amino) -2-phenyl-1-
(2’carboxy biphenyl-4-yl)  benzimidazoles  differ  from  
the  previously reported and related compounds in that 
they produce a potent hypertensive effect upon  oral  
administration.  The earlier series were generally  active  
only  when administered  intravenously.  It has been 
found that 2’-position of  biphenyl  is essential.  Only  
ortho  substituted  acid  possess  both  high  affinity for 
the AII  receptor and oral anti-hypertensive potency. 
Following the discovery of benzimidazole derivatives, 
numerous structural modifications have been made to the 
benzimidazole nucleus to increase the anti-hypertensive 
potency.  






















The renin–angiotensin system (RAS
1
) is known to play 
an important role in cardiovascular regulation
2
  and  the  
maintenance  of  blood  pressure  and  electrolyte  
balance.  AngiotensinII
3
(AngII)  is  active  hormone  of  
RAS  and  it  mediates  a  variety  of  physiological  
functions through stimulation of specific receptors. 
There are at least two distinct receptor sub-types
4-5 
designed as AT1 and AT2. The AT1 receptor mediates 
most of the known AngII physiologic functions such as 
vasoconstriction and aldosterone release. The potential 
role for non peptide. AngII receptor antagonists in the 
treatment of hypertension has well been demonstrated by 
AT1-selective AngII  such as Losartan The physiological 
functions of AT2 receptor are not clearly  defined  but  
AT2  receptor  mediated  effects  of  AngII  have  been  
implicated  in  renal free water clearance
6-7
. AngII 
receptor antagonists are expected to have similar 
therapeutic effects  and  indications  as  the  ACE  
inhibitors  without  unwanted  effects  associated with 
the inhibition  of  other  ACE  mediated  pathways, such  
as  bradykinin  metabolism. Initial  research  in this area 





]-AngII) which displayed  potent  and  
selective  AngII  receptor  antagonist  activity  both  in  
vivo  and  in vitro. However, these peptides had limited 
therapeutic utility due to partial agonist activity short 
duration of action and lack of appreciable oral 
bioavailability
8
. Only in recent years a number of non 
peptides AngII antagonists that show promise as 
inhibitors of the RAS have been reported
9
. All  these  
antagonists  possess  a  central  aromatic  nucleus  
bearing  the pharmacophores indispensable for activity 
and notably a polar function adjacent to biphenyl 
substituents  while  a  polar  function  in  this  area  of  




MATERIAL AND METHODS: 
Melting  points  were  determined  in  open  capillary  
tubes  and  are  uncorrected.  The time  required for 
completion of the reaction was monitored by TLC using 
Silica gel-G plates and spots were  exposed  in  iodine  
chamber. IR spectra were recorded on a Perkin Elmer  
1800 (FTIR) spectrometer 
1
H NMR spectra (DMSO) 
were taken on a DRX-300 spectrometer (300 MHz) 
using TMS as internal standard and chemical shifts are 
expressed in  ppm. 
 
First we synthesized 2-phenyl Benzimidazole.  In this 
method the reactants are condensed in the presence of an 
oxidant such as cupric acetate
11
.  An improvement on the 
conventional method is the use of sodium bisulfite 
addition  adduct  of  the  aldehyde
12 
The reactions  are  
carried  out  in  boiling  ethanol, which gave good yields  
[e.g.  2-phenyl  (90%),2-(3-pyridyl) (97%)] and there is 














SR-1: (2-phenyl Benzimidazole):  
 
                 O-Phenyl diamine  (3.7 gm) was dissolved in a mixture  
of  methanol/water  (200  ml,v/v 1:1).To this, 
benzaldehyde (5.8gm) in  methanol (65ml) and 
Cu(OAc)2 H2O (5gm in  water  (100ml) were added 
sequentially while stirring the solution. The reaction 
mixture was then heated to reflux under vigorous stirring 
for three hours after this a raddish pale precipitate  
                  as formed.  The  mixture  was  filtered  hot  and  then  
washed  with  water  to  afford a yellow solid.  The 
precipitate was redissolved in ethanol (125ml) and to 
this, HCl  (25 ml) and solution of Na2SO4H2O was added 
in water (100 ml). At this stage, the reaction mixture was 
heated at reflux for 1½ hour, resulting in the formation of 
black slurry. Reaction mixture was allowed  to  cool  to  
JPRHC 
Research Article 
JPRHC            January 2010                  Volume 2              Issue 1            103-113  
 
room  temperature  and  filtered  through  a  pad  of  
calcite  to  remove  the precipitated  CuS. The  filtrate  
was  treated  with  ammonia  solution  to  pH  8-9  and  
then concentrated  to  yield  a  reddish  pale  precipitate.  
After filtration  and  vacuum  evaporation, compound 
obtained was reddish solid. 
Yield: 72%, MP 245 -250 C, IR (KBr) (cm
-1
): 3168-
3346 N-H str.), 3050 (ArH str.),1456- 1480 
(C=C & C=N str.), 850 monosub. Benz. 
Ring). H
1
NMR(DMSO): 8.5, (s, br., NH); 
9.12-8.7 (m, 4H, ArH), 8.03-8.55 ( m, 6H, 
ArH).  
SR -2: (5-Nitro 2-phenyl Benzimidazole): 
                 12.75ml of concentrated nitric acid was placed in three 
necked flask and equal quantity of  concentrated 
sulphuric acid (1:1 was added slowly. The mixture  was 
kept in the ice cold water then compound SR No. 1 
(6.32gm) was mixed in portions during ½ hour under 
room  temperature.  After  stirring  continuously  for  10  
hours  30  minutes, the  reaction  mixture was poured 
slowly over crushed ice with stirring. The precipitated 
product was filtered out and washes with cold water. The 
final product SR-2 was formed as yellowish pale.   
Yield: 7.5gm (88%). M.P 165 -170 C 
IR (KBr) (cm
-1
): 3020 (NH str.), 2860(ArH str.), 1540-
1460 (C=C,C=N str.), 1438-1329 (N- 
O str. NO2), 656 (1,2-disubstituted benz.).  
H
1
 NMR(DMSO): 9.3 (s,1H, NH), 7.50-8.03 (m,3H, 
ArH), 7.12 ( m, 5H, ArH).  
SR -3: (Biphenyl Carboxylic acid):  
15  gm  of  potassium  hydroxide  was  heated  at  180 -
200 C  in  a  three  necked  flask  until fusion.  5gm  of  
finely  powdered  of  9H-Fluorenone  was  added  in  five  
portions  over  thirty minutes with vigorous stirring and 
the temperature was maintained at 180 -200 C for 
further half hour. The fusion mixture was then poured in 
ice cold water with stirring. The obtained suspension was 
filtered at pump and then filtrate was acidify with HCl to 
pH-7 resulting in precipitation of byproduct which was 
filtered under suction wash with distilled water and the 
filtrate was again acidify with concerated HCl. The 
precipitated product was filtered under suction and dried 
in air. The product was recrystallized from CCl4 (Carbon 
tetra chloride). Product SR-3 was formed as whitish.  
Yield: 4.5gm (81%). m.p. =116 -128C. 
IR  (KBr):  3500-2650  (OH  Str.),  2960-2820  
(Aromatic,  C-H  str.),  1660  (Carboxylic,   
C-O str.), 756 ( monosub. Benz. Ring).  
H
1
 NMR (DMSO):  9.03 (1H, s, broad, OH), 7.9 (5H, 
m, J=9.0Hz).  
SR-4: (4’ Acetamido methyl biphenyl-2-caboxylic 
acid):  
2gm of SR-3 was dissolved in 6.6ml of concentrated 
H2SO4.After that acetamide (1.89gm)  
and Paraformaldehyde  (0.065)  gm  were  added  
subsequently.  The solution was heated at 65 C along 
with stirring for 3 hours. The hot mixture was poured 
over ice and cold water. The resulting solid was filtered 
out.   
 
                  Yield : 50 mg (21.2%) m.p.-142 -144 C.  
                  IR (KBr) 3400-3300 (Broad O-H and N-H stretching), 
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2858 (C-H str,CH3), 2740 (C-H str., CH2), 1756 
(Carboxylic, C-O str.), 1536 (C=O str.,Amide),  846 (1,4 
disub. Benz. Ring). H
1 
NMR(DMSO):    9.1  
(s,1H,OH),  7.4-7.65  (m,  8H,  ArH),  4.46  (s,  2H,CH2),  
2.10 (s,3H,CH3).  
SR-5: (4’Chloromethylbiphenyl-2-carboxylic acid):  
                  2.4gm of SR-4 was taken in a RBF. 2.598gm of 
phosphorus oxy chloride was added to 4ml  of  DMF  
and  further  addition of  xylene  (6ml).  The reaction 
mixture was refluxed for 7½ hours.  The cold solution 
was washed with water and evaporated to give a light 
yellow Crystalline product.  
Yield: 400mg, m.p. =120 -125 C.  
                 IR(KBr) : 3450-3225 (Broad O-H str.) 3025-3000 
(Aromatic str.), 2875(C-H str., CH2), 1742 (Carboxylic, 
C=O str.),1602-1454 (C=N, C=C str.), 1276 (C-
Ostr),736 (1,2 disubs.benz. ring), 654 (C-Cl str.) H
 
1
NMR(DMSO): 8.95 (s,1H, OH),  7.2-8.23 (m, 8H, 
ArH),  4.46 (s,2H,CH2).   
SR-6: (5-Nitro 2- phenyl-[(2’carboxybiphenyl-4-yl) 
methyl]Benzimidazole:  
                  0.4505gm  of  SR-2  was  dissolved  in  30ml  of  DMF  
(dimethyl  formamide)  and  stirred vigorously with 
1.8gm of potassium carbonate at 37
0
C for one hour. To 
the resulting mixture 0.482gm  of  SR-5  previously  
dissolved  in  30  ml  of  DMF  and  then  was  added  
dropwise  with dropping  funnel  in  1½   hour  the  
reaction  was  allowed  to  proceed  for  further  11hours  
and solvent removed under vacuum. Residue was treated 
with 20ml of dilute HCl and extracted with ethylacetate. 
The organic layer was washed with brine solution, 
distilled water and dried over anhydrous sodium 
sulphate.  The  solvent  was  evaporated  and  a  browish  
amorphous solid (SR-6) was obtained.  
Yield: 0.52 gm, m.p. = 170 -182 C.  
                 IR (KBr): 3425-3122 (Broad O-H str.), 2568 (C-H str., 
CH2), (1650, carboxylic, C=O str.),  1600 (C=N and 
C=Cstr.), 15541360 (N-Ostr., NO2), 1078 (C-N str.), 930 
(1,4 disub. Benz.Ring). H1NMR(DMSO):  9.25  (s,  
br.,OH),  8.75  (m,3H,  ArH),  7.12-7.65  (m,  13H,  
ArH),  4.01 (s,2H,CH2).  
SR-7: (5-amino-2-phenyl-[(2’Carboxy biphenyl-4yl 
methyl]Benzimidazole:  
                0.9342gm of SR-6 was placed in three necked RBF and 
dissolved in anhydrous ethanol and   heated  to  70
0
C  
under  reflux To this, 2.4gm stannous chloride dihydrate 
was added with slow stirring for 45 minutes. The same 
reaction conditions were maintained for further7 hours. 
The  mixture  was  cooled  to  room  temperature  and  
pH  adjusted  to  7  with  5%  sodium hydroxide solution. 
Ethanol was removed under reduced pressure and the 
residue was extracted with dichloromethane. The organic 
layer was washed with brine, distilled water then dried 
over anhydrous sodium sulphate. The solvent was 
removed under vacuum. A yellowish amorphous product 
was obtained.   
Yield: 61%, m.p. =124-136
 
C.  
IR  (KBr):  3350-3105  (Broad,  O-H,  NHstr.),  3050  
(Aromatic,  C-H  str.),  2775  (C-H  str., CH2), 1702 
(Carboxylic, C=O str.), 1602-1554 (C=N,C=C str.), 726 
(1,2 disub.benz.ring). H1
 
NMR(DMSO): 9.8 (s,1H,NH), 
7.4-7.62 (m,8H,ArH), 4.45 (s,2H,CH2), 2.5 (s,3H, CH3).  
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SR-8: (5-nitro-2-ethyl-(2’-carboxybiphenyl-4-
yl)methyl benzimidazole):  
                  5-nitro-2-ethyl-benzimidazole  (0.4502)  was  dissolved  
in  30ml  of  DMF  (dimethyl formamide)  and  stirred  
vigorously  with  1.8gm  of  potassium  carbonate  at  
27
0
C for 1hours. Further reaction was proceeded as in 
SR-6.  
Yield: 68%, m.p. =146-148 .  
IR  (KBr):3545-3320  (Broad  O-H  str.),  2833  (C-H  
str.,CH3),  2758  (C-H  str.,  CH2),  (1726, carboxylic,  
C=O  str.),    1612  (C=N  and  C=Cstr.),  1540-1325  (N-
O  str.,  NO2),  1122  (C-N str.), 840 (1,4 disub. Benz. 
Ring).  
H1NMR(DMSO): 9.3 (s,1H,NH), 7.4-7.62 (m,8H,ArH), 
4.35 (s,2H,CH2), 2.03 (s,3H, CH3).  
SR-9: (5-amino-2-ethyl-[(2’Caboxy biphenyl-4-yl) 
methyl] benzimidazole:  
                 SR-8(0.9645gm) was replaced in three necked RBF and 
dissolved in anhydrous ethanol and heated to70
0
C under 
reflux. Next steps are common to SR-7.  
Yield: 66%, m.p. = 134-1360. 
IR (KBr): 3643-3120 (Board O-H str.), 2966 (C-H str., 
CH3 ), 2867 (C-H str., CH2), 
(1741,Carboxylic, C=O str.),  163 (C=Nand 
C=Cstr.), 1539-1328 (N-O str., No2),1178 (C-
N str.),848 (1,4 disub. Benz. Ring). 
H1 NMR (DMSO): 9.53 (s, 1H,NH), 7.24-7.72 
(m,8H,ArH), 4.38 (s,2H,CH2), 2.13 (s,3H,CH3). 
RESULT AND DISCUSSION 
The compounds reported in this paper SR-6, SR-7, SR-8, 
and SR-9 were the final compound and prepared for 
antihypertensive activity. Taking Losartan as lead 
compound we had fused the benzene ring with imidazole 
and coupling reaction with 4-chloromethy biphenyl 2’-
carboxylic acid (SR-5) to get resulting compounds which 
shows hypertensive activity. At the position 2 we took 2-
phenyl and 2-ethyl. From the study it was found that 
compounds that contain ethyl at position -2 gave better 
result than 2-phenyl. In the biphenyl ring carboxylic 
group at ortho position is necessary for pharmacological 
activity. At 2’ position tetrazolyl moiety had the best 
pharmacological activity was found in the literature. At 
position 5 of benzimidazole NH2 group gives good 
activity. 
 
Pharmacological Investigation of  benzimidazole 
Derivatives for anti-hypertensive activities 




1. Albino normotensive rats (Wister Strain) were 
taken and they were hypertensized by 
cholinomimetic agents for screening of all the 
synthesized benzimidazole derivatives for 
there anti-hypertensive activity. Suspension of 
test compounds was prepared in 1% w/v 
sodium carboxy methyl cellulose (sodium 
CMC) and was administered at dose level of 
50 and 100 microgram/kg animal body weight 
to different groups of five rats each. After 
administration of dose to animal blood 
pressure was measured by normotensive tail 
and cuff method. Using LE-5001 pressure 
meter. Measurement were done after one hour 
and three hours interval in step-wise manner as 
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follows: 
2. One hour after administration of drug sample, 
animal was shifted to the restrainer, which 
restricts the movement of animal. 
3. The tail was cleaned with moist cotton to 
remove the dirty matter and talcum powder 
was sprayed on tail to make its surface smooth. 
4. A tail cuff and pulse transducer was fixed 
around the tail. 
5. Initially animal shows particular pulse level, 
when the pulse rate is within the normal range, 
SBP (systolic blood pressure). DBP (Diastolic 
blood pressure) and MABP (mean arterial 
blood pressure), which is displayed in monitor. 
The pressure can be easily read from the pre-
calibrated monitor. Once all the values are 
displayed the recorder is switched off and for 
next measurement. Some procedures are 




Table 1. Hypertension induced in normotensive rat 
 
Compound                             Exp. Animal                    After 1 hour           After 3 hours 
        Albino (Wistar) Rat SBP DBP   MABP SBP DBP MABP  
    1  142 108 125 158 102 120 
    2  104 106 123 140 104 122 
 SR-6   3  138 104 121 139 103 121 
    4  104 104 122 141 105 122 
    5  141 109 125 140 108 124 
    1  144 108 120 140 105 118 
    2   141 103 119 140 106 117 
 SR-7   3  140 110 124 139 103 118 
    4  139 107 120 140 108 122 
    5  138 105 121 139 107 121 
    1  142 112 127 140 110 111 
    2  140 110 125 140 112 123  
 SR-8   3  141 114 123 141 115 122  
    4  140 113 120 142 114 115  
    5  138 110 125 140 109 119 
    1  142 110 122 140 102 108 
    2  140 107 120 141 106 122 
 SR-9   3  141 110 121 140 104 120  
    4  140 105 111 141 104 122 
    5  141 108 119 138 105 121 
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Table 2. Reduction in boold pressure(mmHg) at a dose of 50µgm/kg animal body weight 
 
        Compound              Exp. Animal                       After 1 hour            After 3 hours 
        Albino (Wistar) Rat SBP DBP   MABP SBP DBP MABP  
    1  130 103 112 122 97 105 
    2  130 105 113 128 100 109 
 SR-6   3  127 99 108 126 99 108 
    4  129 102 111 128 102 111 
    5  130 105 113 128 103 111 
    1  131 106 114 130 104 113 
    2   128 102 111 130 105 113 
 SR-7   3  134 110 118 128 101 110 
    4  131 106 114 133 106 115 
    5  130 104 113 131 104 114 
    1  126 110 115 118 108 111 
    2  124 109 114 120 110 113  
 SR-8   3  127 112 117 122 114 117  
    4  127 111 1161 122 112 115  
    5  126 110 117 120 108 112 
    1  127 108 114 122 101 108 
    2  126 107 113 125 105 112 
 SR-9   3  126 109 115 123 102 109  
    4  125 104 111 124 103 110 
    5  126 107 113 122 103 109 
Table 3: Reduction in blood pressure (mean ± SEM) at a dose of 50µgm/kg animal body weight 
      After 1 hour     After 3 hours 
Compounds SBP      DBP             MABP    SBP      DBP             MABP 
SR – 6      129.2±0.58   102±1.11     111.4±0.92     126.4±1.16    102.2±1.06   108.8±1.11 
SR – 7      130.0±0.96     105.6±1.30  114.0±1.14     130.4±0.81    104.0±0.83   113.0±0.83 
SR – 8      126±0.54        110.4±0.54   115.8±0.58     120.4±0.74   110.4±1.16   113.6±1.07  
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